Roic.ailogo
Powered by AI
US stock · Healthcare sector · Biotechnology
Company Logo

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ

190.83

USD
+0.40
(+0.21%)
Market Closed
-20.75P/E
-77Forward P/E
-0.98P/E to S&P500
23.763BMarket CAP
- -Div Yield
SummaryFinancialsTranscriptsMonitoringClassic View
Upcoming Earnings
26 Jul-31 Jul
Shares Short
5/31/23
5.05M
Short % of Float
5.37%
Short % of Shares Outs.
4.06%
% Held by Insiders
0.32%
% Held by Institutions
98.85%
Beta
0.49
PEG Ratio
0.17
52w. high/low
242.97/122.57
Avg. Daily Volume
0.77M
Return %
Stock
S&P 500
1 year
20.60
(9.05)
3 years
97.25
50.26
5 years
29.35
38.50
Scale: |
High
Low
36.37
16.37
26.36
14.82
19.29
8.79
12.34
5.88
21.38
8.33
67.97
18.61
112.57
47.03
140.00
71.14
98.00
31.38
147.63
35.98
153.99
60.27
125.72
65.81
167.33
84.97
212.00
124.00
242.97
117.58
242.39
179.19
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
1.32
2.34
2.41
2.38
1.95
1.33
0.77
0.68
0.49
0.55
0.99
0.74
2.01
4.29
7.13
8.53
Earnings per share
(2.21)
(0.64)
(1.14)
(1.04)
(1.36)
(2.11)
(1.45)
(4.85)
(3.45)
(4.79)
(5.42)
(7.57)
(8.11)
(7.46)
(7.20)
(9.30)
FCF per share
4.88
1.33
(1.85)
(2.12)
(2.08)
(2.47)
(1.18)
(2.35)
(2.41)
(4.35)
(5.38)
(6.85)
(3.83)
(5.96)
(6.06)
(4.41)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.20
0.26
0.12
0.11
0.03
0.17
0.07
0.12
0.15
0.75
1.15
1.26
1.28
0.61
0.64
(0.04)
Book Value per sh.
5.15
4.92
4.27
3.76
2.78
2.67
4.39
12.60
15.06
10.75
19.51
12.94
13.17
8.84
4.97
(1.30)
Comm.Shares outs.
39
41
42
42
42
50
62
74
84
86
91
101
109
115
118
122
Avg. annual P/E ratio
(10.7)
(42.4)
(17.7)
(14.5)
(6.6)
(6.8)
(27.5)
(15.3)
(30.5)
(12.9)
(14.9)
(13.6)
(10.5)
(17.6)
(22.9)
(18.5)
P/E to S&P500
(0.6)
(2.0)
(0.2)
(0.7)
(0.4)
(0.5)
(1.6)
(0.8)
(1.5)
(0.6)
(0.6)
(0.5)
(0.4)
(0.5)
(0.8)
(0.9)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
51
96
101
100
83
67
47
51
41
47
90
75
220
493
844
1,037
Operating margin
(183.1)%
(28.9)%
(47.9)%
(44.1)%
(66.2)%
(194.0)%
(197.0)%
(801.0)%
(720.3)%
(900.3)%
(556.2)%
(1,087.6)%
(427.5)%
(168.1)%
(83.9)%
(75.7)%
Depreciation (m)
4
6
6
5
5
9
10
12
19
15
13
6
54
74
90
86
Net profit (m)
(85)
(26)
(48)
(44)
(58)
(106)
(89)
(360)
(290)
(410)
(491)
(761)
(886)
(858)
(853)
(1,131)
Income tax rate
(6.5)%
(2.8)%
(1.2)%
(1.2)%
- -
9.1%
2.9%
10.0%
- -
- -
- -
(0.1)%
(0.1)%
(0.3)%
(0.1)%
(0.4)%
Net profit margin
(167.9)%
(27.3)%
(47.3)%
(43.5)%
(69.7)%
(158.9)%
(189.2)%
(712.8)%
(705.8)%
(869.6)%
(545.9)%
(1,016.6)%
(403.2)%
(174.1)%
(101.0)%
(109.0)%
Working capital (m)
381
343
183
152
71
77
200
651
1,043
540
1,620
1,021
1,363
1,530
2,113
1,924
Long-term debt (m)
3
- -
- -
- -
- -
- -
- -
- -
- -
150
30
30
276
484
957
1,278
Equity (m)
199
202
178
158
118
134
270
936
1,265
920
1,766
1,302
1,439
1,016
588
(158)
ROIC
(20.8)%
(5.6)%
(11.4)%
(14.1)%
(28.1)%
(44.0)%
(24.1)%
(36.4)%
(21.5)%
(35.5)%
(25.9)%
(52.5)%
(41.7)%
(27.4)%
(24.1)%
(35.1)%
Return on capital
(16.2)%
(4.4)%
(8.6)%
(10.3)%
(20.0)%
(40.2)%
(21.6)%
(36.9)%
(20.5)%
(31.8)%
(24.0)%
(46.4)%
(35.6)%
(22.6)%
(19.5)%
(27.4)%
Return on equity
(42.9)%
(13.0)%
(26.7)%
(27.5)%
(48.9)%
(79.1)%
(33.0)%
(38.5)%
(22.9)%
(44.6)%
(27.8)%
(58.5)%
(61.6)%
(84.5)%
(145.0)%
714.9%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
23 Feb · 2023 | Q4
All numbers in millions
Total liabilities
$ 3,705
Total assets
$ 3,546
Long-term debt
$ 1,278
Cash and equiv.
$ 866
Goodwill
$ - -
Retained earnings
$ (6,569)
Common stock
122
Enterprise Value
$ 24,175
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
1,874
2,436
2,164
Receivables
102
199
238
Inventory
75
86
129
Other
63
411
531
Current assets
2,115
2,809
2,692
Acc. Payable
52
73
98
Debt due
37
41
42
Other
496
582
628
Current liabilities
585
696
768
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
22.88%
102.95%
54.34%
Cash flow
(25.35)%
0.97%
35.17%
Earnings
32.64%
11.31%
49.54%
Dividends
- -
- -
- -
Book value
(126.90)%
(46.97)%
14.66%
Insider Trading
Type
Shares
Date
Kellogg Peter N
Award
4,948
03/07/23
Garg Pushkal
Exempt
2,500
03/03/23
Garg Pushkal
Exempt
2,500
03/03/23
Garg Pushkal
Sale
18,072
03/03/23
Garg Pushkal
Exempt
2,500
03/03/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
99
104
126
164
493
2021
178
221
188
259
844
2022
213
225
264
335
1,037
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.58)
(1.56)
(2.20)
(2.12)
(7.46)
2021
(1.69)
(1.60)
(1.73)
(2.18)
(7.20)
2022
(1.98)
(2.28)
(3.34)
(1.71)
(9.30)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Full-time employees:
1,665
City:
Cambridge
Address:
675 West Kendall Street
IPO:
May 28, 2004
CIK:
0001178670
Website:
alnylam.com
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Recent News